Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. 1998

O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
Dept. of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Doxorubicin (DOX) has a wide spectrum of antitumor activity with dose-related cardiotoxicity as a major side effect. This cardiotoxicity has been suggested to result from the generation of oxygen-free radicals. The objective of the present study was to investigate the influence of the antioxidant, thymoquinone (TQ) on cardiotoxicity and antitumor activity of DOX in mice. TQ (8 mg/kg/day, p.o.) administered with drinking water starting 5 days before a single i.p. injection of DOX (20 mg/kg) and continuing during the experimental period ameliorated the DOX-induced cardiotoxicity in mice. This finding was evidenced by significant reductions in serum lactate dehydrogenase and creatine kinase elevated levels and further supplemented by histopathological examination of cardiac tissue. TQ did not alter the plasma and heart DOX levels as monitored by fluorometric analysis. In in vivo study on mouse Ehrlich ascites carcinoma tumor, it could then be shown that TQ does not interfere with the antitumor activity of DOX. The current data support TQ as a potentially selective cytoprotective agent, which may ameliorate cardiotoxicity without decreasing DOX antitumor activity.

UI MeSH Term Description Entries
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D002286 Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms. Ehrlich Ascites Tumor,Ascites Tumor, Ehrlich,Ehrlich Tumor Carcinoma,Tumor, Ehrlich Ascites
D003402 Creatine Kinase A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins. Creatine Phosphokinase,ADP Phosphocreatine Phosphotransferase,ATP Creatine Phosphotransferase,Macro-Creatine Kinase,Creatine Phosphotransferase, ATP,Kinase, Creatine,Macro Creatine Kinase,Phosphocreatine Phosphotransferase, ADP,Phosphokinase, Creatine,Phosphotransferase, ADP Phosphocreatine,Phosphotransferase, ATP Creatine
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic

Related Publications

O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
September 2005, Phytotherapy research : PTR,
O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
July 1999, The Journal of surgical research,
O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
November 2018, Biochemistry,
O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
October 2015, Journal of cellular and molecular medicine,
O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
July 2022, Archives of toxicology,
O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
January 2020, Oxidative medicine and cellular longevity,
O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
May 2014, BMC pharmacology & toxicology,
O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
January 2019, Cardiology research and practice,
O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
January 1998, Oncology research,
O A al-Shabanah, and O A Badary, and M N Nagi, and N M al-Gharably, and A C al-Rikabi, and A M al-Bekairi
March 2002, Biochemical pharmacology,
Copied contents to your clipboard!